F 200

Drug Profile

F 200

Alternative Names: EOS 200-F; Eos 200F; F-200; Ocular neovascularisation therapies - Protein Design Labs

Latest Information Update: 17 Mar 2005

Price : $50

At a glance

  • Originator PDL BioPharma
  • Class Eye disorder therapies; Fab fragments
  • Mechanism of Action Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 17 Mar 2005 Discontinued - Preclinical for Age-related macular degeneration in USA (Ophthalmic)
  • 12 Oct 2004 Preclinical data from a media release have been added to the Eye Disorders pharmacodynamics section
  • 23 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top